X
Upload your Marketing & Sales content on your company Virtual Booth, click HERE.
Details:
The Company is initiating nonclinical studies to elucidate the mechanism for the observed transaminitis, which was not predicted by extensive GLP toxicology studies of THB001 nor observed in the Company’s Phase 1a study.
Lead Product(s): THB001
Therapeutic Area: Immunology Product Name: THB001
Highest Development Status: Phase IProduct Type: Small molecule
Partner/Sponsor/Collaborator: Not Applicable
Deal Size: Not Applicable Upfront Cash: Not Applicable
Deal Type: Not Applicable December 15, 2022
Details:
THB001, is a highly selective, oral small-molecule inhibitor of KIT, a cell surface receptor that serves as the master regulator of mast cell function and survival.
Lead Product(s): THB001
Therapeutic Area: Immunology Product Name: THB001
Highest Development Status: Phase IProduct Type: Small molecule
Partner/Sponsor/Collaborator: Morgan Stanley
Deal Size: $10.9 million Upfront Cash: Undisclosed
Deal Type: Public Offering September 14, 2022
Details:
This financing will fund development of the company’s lead candidate, THB001, through the next phase of human studies for the initial indication of chronic urticaria.
Lead Product(s): THB001
Therapeutic Area: Dermatology Product Name: THB001
Highest Development Status: Phase IProduct Type: Small molecule
Partner/Sponsor/Collaborator: Atlas Venture
Deal Size: $105.0 million Upfront Cash: Undisclosed
Deal Type: Series B Financing February 16, 2022
FULL SCREEN VIEW Click here to open all results in a new tab [this preview display 10 results] 
Market Place
